Health

FDA authorized the first at-home combo test for flu, COVID, and RSV. This multiplex molecular test could redefine home diagnostics this winter.

The Medtronic insulin pump recall exposes critical cybersecurity flaws that put diabetic patients at risk. A must-read analysis.

FDA red dye No.3 ban forces food and pharma to scramble. The hidden science: why a 1960 law finally caught up with a ubiquitous additive.

Microplastics in brain tissue are rising. A new Nature Medicine study reveals alarming concentrations and links to potential neurological damage.

A late-stage trial for a pancreatic cancer vaccine failed to improve survival, dashing hopes for a new immunotherapy approach.

RSV vaccine FDA panel rejection changes everything. This decision impacts millions of seniors and the future of mRNA vaccines for respiratory viruses.

CDC reports first severe H5N1 bird flu hospitalization in U.S. — a sign the virus may be adapting.

In a surprise vote, FDA advisors rejected updating COVID-19 vaccines for fall 2025, citing insufficient data on new variants. The FDA panel rejects COVID-19 vaccine update, altering booster plans.

The FDA Alzheimer's drug approval for Eli Lilly's Kisunla creates a logistical nightmare with complex dosing and monitoring requirements that challenge healthcare infrastructure.

FDA's historic approval of a CAR-T-based prostate cancer gene therapy marks a turning point in oncology, but cost and complexity loom.

The FDA's new dementia trial guidance aims to accelerate drug development but raises serious ethical concerns about informed consent.

An FDA panel rejected a specific strain update for the fall COVID-19 vaccine, revealing tensions between scientific data and real-world readiness.